Skip to content
Screener

Nektar Therapeutics NKTR Q3 2026 earnings

Reported November 12, 2026 · After market close

Revenue$9.4MMiss by $887.5K
EPS-$1.63Beat by $0.44
Revenue estimate$10.3M
EPS estimate-$2.07
“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development. We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned. The strong body of clinical and translational data generated to-date for rezpegaldesleukin reinforce our conviction in its novel and differentiated Treg mechanism, which targets multiple inflammatory pathways that underpin chronic autoimmune disease. We believe rezpegaldesleukin has the potential to offer an important new therapeutic approach for patients, and we're focused on advancing to our topline data readouts in the summer of 2028 with the first BLA filing in 2029.”
Howard Robin

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$9.4M-20.4%
Operating income-$57.8M-82.5%
Net income-$55.7M-56.7%
EPS (diluted)-$1.63+12.8%

Balance sheet

See full
Cash & equivalents$34.7M+206%
Total debt$73.9M-19.6%
Total equity$849.7M+899%
Total assets$1.0B+244%

Cash flow

See full
Operating cash flow-$71.9M-47.5%
CapEx$398.0K+249%
Free cash flow-$72.3M-48.0%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$1.29B+9.5%
Enterprise value$1.33B+5.6%
P/S24.8×+5.9×

Profitability

See full
Operating margin-319.8%—
Net margin-339.7%+663pp
FCF margin-493.4%+814pp

Returns & leverage

See full
Return on equity-37.9%-16.9pp
Debt / equity0.1×-1.0×
Current ratio9×+4.8×

Segments

By product

See full
Non Cash Royalty Revenue Related To Sale Of Future Royalties$9.4M-18.3%

FAQ

When did Nektar Therapeutics report Q3 2026 earnings?
Nektar Therapeutics (NKTR) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Nektar Therapeutics's Q3 2026 revenue and EPS?
Nektar Therapeutics reported revenue of $9.4M and eps of $-1.63 for Q3 2026.
Did Nektar Therapeutics beat estimates in Q3 2026?
Revenue missed the consensus estimate of $10.3M by $887.5K. EPS beat the consensus estimate of $-2.07 by $0.44.
How did Nektar Therapeutics's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 20.4% from $11.8M a year earlier and eps grew 11.9% from $-1.85.
Where can I find Nektar Therapeutics's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-118964) and the 10-Q periodic report (0001193125-26-458868) directly on SEC EDGAR. The filing index links above go to sec.gov.